Robots are getting better at sniffing out smells thanks to improvements in electronic noses (e-noses). A comprehensive review ...

Adaptive systems were supposed to simplify decision-making. Instead of hard-coded rules, engineers built models that could learn from data, respond to change, and improve over time. That promise still ...

Accurately tracking atmospheric greenhouse gases requires not only fast predictions but also reliable estimates of ...

X may soon provide more insight into how its algorithm works. On Saturday, Elon Musk posted on the platform to say that the company "will make the new X algorithm, including all code used to determine ...

While the creation of this new entity marks a big step toward avoiding a U.S. ban, as well as easing trade and tech-related tensions between Washington and Beijing, there is still uncertainty ...

Instagram is rolling out a new tool called Your Algorithm, and it gives you direct control over the videos that fill your Reels tab. Your interests shift as time moves on. Now your feed can shift with ...

Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the treatment of HIV met the primary endpoint in the late-stage ARTISTRY-2 study.

– Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...